376 related articles for article (PubMed ID: 29303368)
21. FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.
Cools J
Verh K Acad Geneeskd Belg; 2005; 67(3):169-76. PubMed ID: 16089297
[TBL] [Abstract][Full Text] [Related]
22. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
Gotlib J; Cools J; Malone JM; Schrier SL; Gilliland DG; Coutré SE
Blood; 2004 Apr; 103(8):2879-91. PubMed ID: 15070659
[TBL] [Abstract][Full Text] [Related]
23. Detection of FIP1L1-PDGFRA fusion gene-positive cells in the skin lesion of a patient with hypereosinophilic syndrome.
Kitayama S; Makino T; Yoto A; Mori S; Furukawa F; Torai R; Mizawa M; Shimizu T
Clin Exp Dermatol; 2023 Mar; 48(4):364-367. PubMed ID: 36763740
[TBL] [Abstract][Full Text] [Related]
24. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A
Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453
[TBL] [Abstract][Full Text] [Related]
26. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
[TBL] [Abstract][Full Text] [Related]
27. Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome.
Helbig G; Hus M; Hałasz M; Dudziński M; Więcławek A; Stachowicz M; Soja A; Kyrcz-Krzemień S
Med Oncol; 2012 Jun; 29(2):1073-6. PubMed ID: 21258876
[TBL] [Abstract][Full Text] [Related]
28. [New insights into hypereosinophilic syndromes].
Bletry O; Kahn JE; Ackermann F; Charles P; Legrand F
Bull Acad Natl Med; 2010 Mar; 194(3):547-59; discussion 559-60. PubMed ID: 21171248
[TBL] [Abstract][Full Text] [Related]
29. Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.
Yamada Y; Cancelas JA; Rothenberg ME
Int Arch Allergy Immunol; 2009; 149 Suppl 1():102-7. PubMed ID: 19494514
[TBL] [Abstract][Full Text] [Related]
30. [Efficiency of imatinib in polyserositis revealing a FIP1L1-PDGFRA-negative hypereosinophilic syndrome].
Green L; Kahn JE; Dufour JF; Le Scanff J; Charhon A; Broussolle C; Sève P
Rev Med Interne; 2010 Apr; 31(4):305-8. PubMed ID: 20167399
[TBL] [Abstract][Full Text] [Related]
31. Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group.
Helbig G; Lewandowski K; Świderska A; Rodzaj M; Seferyńska I; Gajkowska-Kulik J
Pol Arch Intern Med; 2020 Mar; 130(3):255-257. PubMed ID: 32125294
[No Abstract] [Full Text] [Related]
32. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.
Pardanani A; Tefferi A
Leuk Res; 2004 May; 28 Suppl 1():S47-52. PubMed ID: 15036941
[TBL] [Abstract][Full Text] [Related]
33. [Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib].
Wolf D; Gastl G; Rumpold H
Dtsch Med Wochenschr; 2004 Oct; 129(40):2104-6. PubMed ID: 15455302
[TBL] [Abstract][Full Text] [Related]
34. Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia.
Fassnacht F; Roumier M; Fouret P; Levy V; Varnous S; Russel S; Lefevre G; Kahn JE
Transplantation; 2015 Nov; 99(11):e176-7. PubMed ID: 26492057
[No Abstract] [Full Text] [Related]
35. FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement.
Williams C; Kalra S; Nath U; Bown N; Wilson V; Wilkins BS; Neylon AJ
J Clin Pathol; 2008 May; 61(5):677-80. PubMed ID: 18256119
[TBL] [Abstract][Full Text] [Related]
36. Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics.
Dahabreh IJ; Giannouli S; Zoi C; Zoi K; Voulgarelis M; Moutsopoulos HM
Medicine (Baltimore); 2007 Nov; 86(6):344-354. PubMed ID: 18004179
[TBL] [Abstract][Full Text] [Related]
37. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib.
Pitini V; Sturniolo G; Cavallari V; Arrigo C
Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645
[No Abstract] [Full Text] [Related]
38. [Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome].
Martinaud C; Souraud JB; Cournac JM; Pons S; Ménard G; de Jaureguiberry JP; Brisou P
Rev Med Interne; 2011 May; 32(5):e66-8. PubMed ID: 20633965
[TBL] [Abstract][Full Text] [Related]
39. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.
Klion AD; Robyn J; Maric I; Fu W; Schmid L; Lemery S; Noel P; Law MA; Hartsell M; Talar-Williams C; Fay MP; Dunbar CE; Nutman TB
Blood; 2007 Nov; 110(10):3552-6. PubMed ID: 17709602
[TBL] [Abstract][Full Text] [Related]
40. Pemphigus-like hypereosinophilic syndrome with FIP1L1-PDGFRA fusion gene: A challenging and uncommon clinical presentation.
Curto-Barredo L; Segura S; Ishii N; Hashimoto T; Mascaró JM; Espinet B; Besses C; Pujol RM
J Dermatol; 2019 Jun; 46(6):531-534. PubMed ID: 31021002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]